EKF DIAGNOSTICS HOLDINGS PLC EKF Diagnostics Holdings plc (AIM: EKF) announces that on 21 March 2017, the Company was notified that Harwood Capital LLP ('Harwood') acquired 8,000,000 ordinary shares of 1 pence each in the capital of the Company ('Ordinary Shares') as investment manager to North Atlantic Smaller Companies Investment Trust PLC ('NAIT'). Christopher Mills, the Company's Non-Executive Chairman, is a partner and Chief Investment Officer of Harwood and a director and shareholder in NAIT.
Following the above transaction, which was completed on 20 March 2017 at a price of 19.5p pence per share, NAIT's interest is now in 98,000,000 Ordinary Shares, representing 21.12% of the Company's issued share capital. The interests of Oryx International Growth Fund Limited ('Oryx', whose investment adviser is Harwood) remains as previously disclosed in 40,000,000 Ordinary Shares, representing 8.62% of the Company's issued share capital. Mr Mills is also a director and shareholder in Oryx.
The total indirect beneficial interest of Mr Mills is, following the above transaction, therefore now in 138,000,000 Ordinary Shares, representing 29.73% of the Company's issued share capital.
| EKF Diagnostics Holdings plc Julian Baines, CEO Richard Evans, Finance Director and COO |
00 44 29 2071 0570 |
| N+1 Singer Alex Price / Alex Laughton-Scott | 00 44 20 7496 3000 |
Walbrook PR Limited |
00 44 20 7933 8780 or ekf@walbrookpr.com 00 44 7980 541 893 00 44 7584 391 303 |
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Harwood Capital LLP, as investment manager to North Atlantic Smaller Companies Investment Trust PLC ('NAIT') | ||||
2 | Reason for the notification | |||||
a) | Position/status | Christopher Mills, the Company's Non-Executive Chairman, is a partner and Chief Investment Officer of Harwood Capital LLP and a director and shareholder in NAIT | ||||
b) | Initial notification /Amendment | Initial Notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | EKF Diagnostics Holdings plc | ||||
b) | LEI | 213800DXTF3EAUK1AR05 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrumentIdentification code | Ordinary shares of 1p each ('Ordinary Shares') ISIN Code: GB0031509804 | ||||
b) | Nature of the transaction | Acquisition of shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) |
Aggregated information | n/a | ||||
e) | Date of the transaction | 20 March 2017 | ||||
f) | Place of the transaction | London Stock Exchange | ||||
EKF Diagnostics Holdings plc published this content on 21 March 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 21 March 2017 15:56:10 UTC.
Original documenthttps://www.ekfdiagnostics.com/pdmr-dealing.html
Public permalinkhttp://www.publicnow.com/view/257233A93116802C9180210D0A5511484D267309
